Acute Hepatic Porphyria (AHP)

International Congress of Inborn Errors Metabolism (ICIEM) 2025

Congress Details

September 2-6, 2025

Kyoto, Japan

The material below is provided to support scientific exchange and pertains to select congress resources. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.

All congress materials are copyrighted by Alnylam. Permission is required to copy or distribute.

For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.

Congress Materials

Presentation Type

Presentation

Location

Kyoto, Japan

Title

Long-term clinical outcomes of patients with acute hepatic porphyria who were not attack-free after 6 months of givosiran treatment: a subgroup analysis of the phase 3 ENVISION study

International Congress of Inborn Errors Metabolism (ICIEM) 2025

Congress Details

Congress Materials

Related Materials

Elevated homocysteine is negatively correlated with plasma cystathionine β ‐synthase activity in givosiran‐treated patients

Clinical features of acute attacks, chronic symptoms, and long-term complications among patients with acute hepatic porphyria in Japan: a real-world claims database study

Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial

Pharmacokinetic-Pharmacodynamic Model of Urinary δ-Aminolevulinic Acid Reduction After Givosiran Treatment in Patients with Acute Hepatic Porphyria

Population Pharmacokinetic Analysis of the RNAi Therapeutic Givosiran in Patients with Acute Hepatic Porphyria

Quantifying the Impact of Acute Hepatic Porphyria on Well-Being via Patient-Reported Outcomes: Results from the Porphyria Worldwide Patient Experience Research (POWER) Study

Warning !

Confirmation !

Update Password